Compare Duke Energy Corp (DUK) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Duke Energy Corp vs Eli Lilly And Co — how do they compare? Duke Energy Corp trades at $116.8 (market cap $91.10B), while Eli Lilly And Co trades at $1,169 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 11.4× Duke Energy Corp's market cap, and Duke Energy Corp pays the higher dividend (3.71%). Which is the better fit depends on your goals — on Pluang, investors hold Duke Energy Corp for 74 Days and Eli Lilly And Co for 93 Days on average.
| DUK | LLY | |
|---|---|---|
Market Cap | $91.10B | $1.04T |
Volume | 4,199,050 | 3,064,878 |
Sector | Utilities | Health |
52-Week High | $133.46 | $1.28K |
52-Week Low | $113.23 | $799.57 |
Typical Hold Time | 74 Days | 93 Days |
Enterprise Value | $183.61B | $1.09T |
Dividend Yield | 3.71% | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Duke Energy (DUK) trades at $115.5, down 0.14% on the day, amid a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats, revenue growth from $28.8B in 2022 to $32.2B in 2025, and a net income margin of 15.78%. Recent news highlights dividend stability and data center-driven growth opportunities, though rising Treasury yields pressure utility stocks.
DUK offers a balanced outlook with steady dividends and growth from data center demand, but faces risks from high debt levels and interest rate sensitivity. Analyst consensus is mixed with a $135.33 price target, suggesting 17% upside, supported by a 43.75% buy rating. Investors should weigh solid profitability against macroeconomic headwinds.
Eli Lilly (LLY) trades at $1,188.72, up 2.7% on the day, with a bullish technical signal and strong fundamentals. Recent earnings beats, robust revenue growth to $65.18B in 2025, and a net income margin of 33.53% highlight operational strength. Positive news flow centers on next-generation weight-loss drugs, with analyst consensus bullish and a price target of $1,350.
Outlook remains positive given pipeline catalysts in obesity/diabetes markets, though high valuations (P/E 39.9) and rising debt levels pose risks. Competitive intensity and regulatory scrutiny are watchpoints, but institutional support and earnings momentum underpin further upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Duke Energy Corp
Duke Energy is one of the largest U.S. utilities, with regulated utilities in the Carolinas, Indiana, Florida, Ohio, and Kentucky that deliver electricity to nearly 8 million customers. Its natural gas utilities serve more than 1.5 million customers. Duke operates in three major segments: electric utilities and infrastructure
Read more on DUK →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
